Asia Pacific Active Pharmaceutical Ingredient Cdmo Market Size & Outlook
- HC Outsourcing
- CMO/CDMO
- Active Pharmaceutical Ingredient CDMO Market Outlook
- CMO/CDMO
Global Market
Related Markets
Ask a question about the active pharmaceutical ingredient cdmo market
Asia Pacific active pharmaceutical ingredient cdmo market highlights
- The Asia Pacific active pharmaceutical ingredient cdmo market generated a revenue of USD 32,118.9 million in 2025.
- The market is expected to grow at a CAGR of 9.8% from 2026 to 2033.
- In terms of segment, traditional active pharmaceutical ingredient (traditional api) was the largest revenue generating product in 2025.
- Antibody Drug Conjugate (ADC) is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2026 to 2033.
Asia Pacific data book summary
| Market revenue in 2025 | USD 32,118.9 million |
| Market revenue in 2033 | USD 67,120.6 million |
| Growth rate | 9.8% (CAGR from 2026 to 2033) |
| Largest segment | Traditional active pharmaceutical ingredient (traditional api) |
| Fastest growing segment | Antibody Drug Conjugate (ADC) |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Antibody Drug Conjugate (ADC), Traditional Active Pharmaceutical Ingredient (Traditional API), Highly Potent Active Pharmaceutical Ingredient (HP-API) |
| Key market players worldwide | Recipharm, Thermo Fisher Scientific Inc, Samsung BioLogics, Lonza Group Ltd, Catalent Inc, Siegfried Holding AG, Piramal Pharma Solutions, Boehringer Ingelheim, Cambrex, CordenPharma |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 28.0% of the global active pharmaceutical ingredient cdmo market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 67,120.6 million by 2033.
Asia Pacific’s active pharmaceutical ingredient CDMO market is expected to witness lucrative growth over the forecast period, owing to the increasing scope of opportunities, especially in Japan, China, and India. It accounted for 46.4% of the global market in 2020.
Furthermore, availability of skilled workforce at a lower cost than developed economies, such as the U.S., is anticipated to propel the market. China holds the largest share in Asia Pacific market, primarily due to high pharmaceutical R&D investment.
Asia Pacific has a number of regulatory agencies, such as Pharmaceuticals and Medical Devices Agency (PMDA) in Japan; the Ministry of Food and Drug Safety (MFDS) in South Korea; and the Therapeutic Goods Administration (TGA) in Australia.
No credit card required*
Publish Date: Sep 16, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Active Pharmaceutical Ingredient CDMO Market Scope
Active Pharmaceutical Ingredient CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | www.boehringer-ingelheim.com/ |
| Catalent Inc | View profile | 17,219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | www.catalent.com |
| Siegfried Holding AG | View profile | 4,180 | Untere Bruehlstrasse 4, Zofingen, Switzerland, CH-4800 | www.siegfried.ch |
| Recipharm | View profile | 1001-5000 | Jordbro, Stockholms Lan, Sweden, Europe | www.recipharm.com |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.samsungbiologics.com/ |
| Piramal Pharma Solutions | View profile | 1001-5000 | Riverview, Michigan, United States, North America | www.piramalpharmasolutions.com/ |
| CordenPharma | View profile | 5001-10000 | Plankstadt, Baden-Wurttemberg, Germany, Europe | cordenpharma.com |
| Cambrex | View profile | 1001-5000 | East Rutherford, New Jersey, United States, North America | www.cambrex.com |
Asia Pacific Active Pharmaceutical Ingredient CDMO Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Active Pharmaceutical Ingredient CDMO Market Outlook will help companies and investors design strategic landscapes.
Traditional Active Pharmaceutical Ingredient (Traditional Api) was the largest segment with a revenue share of 46.93% in 2025.
Horizon Databook has segmented the Asia Pacific active pharmaceutical ingredient cdmo market based on antibody drug conjugate (adc), traditional active pharmaceutical ingredient (traditional api), highly potent active pharmaceutical ingredient (hp-api) covering the revenue growth of each sub-segment from 2021 to 2033.
Asia Pacific’s active pharmaceutical ingredient CDMO market is expected to witness lucrative growth over the forecast period, owing to the increasing scope of opportunities, especially in Japan, China, and India. It accounted for 46.4% of the global market in 2020.
Furthermore, availability of skilled workforce at a lower cost than developed economies, such as the U.S., is anticipated to propel the market. China holds the largest share in Asia Pacific market, primarily due to high pharmaceutical R&D investment.
Asia Pacific has a number of regulatory agencies, such as Pharmaceuticals and Medical Devices Agency (PMDA) in Japan; the Ministry of Food and Drug Safety (MFDS) in South Korea; and the Therapeutic Goods Administration (TGA) in Australia.
- Asia Pacific Active Pharmaceutical Ingredient Cdmo Market Product Outlook (Revenue, USD Million , 2021-2033)
- Traditional Active Pharmaceutical Ingredient (Traditional API)
- Highly Potent Active Pharmaceutical Ingredient (HP-API)
- Antibody Drug Conjugate (ADC
- Others
- Asia Pacific Active Pharmaceutical Ingredient Cdmo Market Synthesis Outlook (Revenue, USD Million , 2021-2033)
- Synthetic
- Biotech
- Asia Pacific Active Pharmaceutical Ingredient Cdmo Market Drug Outlook (Revenue, USD Million , 2021-2033)
- Innovative
- Generics
- Asia Pacific Active Pharmaceutical Ingredient Cdmo Market Workflow Outlook (Revenue, USD Million , 2021-2033)
- Clinical
- Commercial
- Asia Pacific Active Pharmaceutical Ingredient Cdmo Market Application Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- Hormonal
- Glaucoma
- Cardiovascular disease
- Diabetes
- Others
Reasons to subscribe to Active Pharmaceutical Ingredient CDMO Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Active Pharmaceutical Ingredient CDMO Market Outlook databook
- Our clientele includes a mix of Active Pharmaceutical Ingredient CDMO Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific Active Pharmaceutical Ingredient CDMO Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific Active Pharmaceutical Ingredient CDMO Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Asia Pacific Active Pharmaceutical Ingredient Cdmo Market, 2021-2033 (US$M)
Asia Pacific active pharmaceutical ingredient cdmo market statistics, by product, 2021-2033 (US$M)
